Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, Multicenter, Double-Blind, Phase 3 Trial Comparing the Efficacy of Ipilimumab plus Etoposide/Platinum versus Etoposide/Platinum in Subjects with Newly Diagnosed Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC)

Next Previous
X
Search
Trial Profile

Randomized, Multicenter, Double-Blind, Phase 3 Trial Comparing the Efficacy of Ipilimumab plus Etoposide/Platinum versus Etoposide/Platinum in Subjects with Newly Diagnosed Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 04 Mar 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ipilimumab (Primary) ; Carboplatin; Cisplatin; Etoposide
  • Indications Small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Bristol-Myers Squibb

    • Most Recent Events

    • 31 Jan 2021 Results of systemic review of 6 trials (Reck et al 2013, Reck et al 2016, IMpower 133, EA5161, KEYNOTE-604, CASPIAN) assessing difference in both efficacy and safety profiles among different Immuno-Oncology (IO) agents in combination with platinum-based CT in ES-SCLC patients according to different ICIs subtypes, presented at the 2020 World Conference on Lung Cancer.
    • 03 May 2019 This trial has been completed in Belgium, according to European Clinical Trials Database.
    • 14 Jun 2017 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top